share_log

藥明康德：海外監管公告

WUXI APPTEC: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

Hong Kong Stock Exchange ·  Apr 29 09:16
Summary by Moomoo AI
药明康德於2024年4月29日召開第三屆董事會第十一次會議，會議由董事長李革博士主持，並通過了多項重要決議。其中包括審議通過了公司2024年第一季度報告，該報告已經獲得審計委員會的審議通過。此外，董事會還審議通過了《2024年H股獎勵信托計劃（草案）》，計劃將使用不超過20億港元的資金購買H股股票作為授予獎勵股票的來源。該獎勵計劃的具體授予條件將與公司2024年的營業收入目標掛鉤。會議還通過了提請股東大會授權董事會處理與H股獎勵信托計劃相關的事宜，以及變更公司註冊資本和修改公司章程的議案。所有通過的議案均將提交股東大會審議。會議最後決定召開2023年年度股東大會及2024年第二次A股和H股類別股東會議。
药明康德於2024年4月29日召開第三屆董事會第十一次會議，會議由董事長李革博士主持，並通過了多項重要決議。其中包括審議通過了公司2024年第一季度報告，該報告已經獲得審計委員會的審議通過。此外，董事會還審議通過了《2024年H股獎勵信托計劃（草案）》，計劃將使用不超過20億港元的資金購買H股股票作為授予獎勵股票的來源。該獎勵計劃的具體授予條件將與公司2024年的營業收入目標掛鉤。會議還通過了提請股東大會授權董事會處理與H股獎勵信托計劃相關的事宜，以及變更公司註冊資本和修改公司章程的議案。所有通過的議案均將提交股東大會審議。會議最後決定召開2023年年度股東大會及2024年第二次A股和H股類別股東會議。
Ming Kang Pharmaceutical held the 11th meeting of the Third Board of Directors on April 29, 2024, chaired by Chairman Dr. Li Keung, and passed several important resolutions. This includes the approval of the Company's 2024 First Quarter Report, which has been approved by the Audit Committee. In addition, the Board of Directors approved the “H Share Award Trust Scheme 2024 (Draft)”, which will use funds of no more than HK$20 billion to purchase H shares as a source for awarding bonus shares. The specific award conditions of the incentive program will be linked to the company's 2024 operating revenue target. The meeting also passed a motion to the General Meeting to authorize the Board of Directors to deal with matters related to the...Show More
Ming Kang Pharmaceutical held the 11th meeting of the Third Board of Directors on April 29, 2024, chaired by Chairman Dr. Li Keung, and passed several important resolutions. This includes the approval of the Company's 2024 First Quarter Report, which has been approved by the Audit Committee. In addition, the Board of Directors approved the “H Share Award Trust Scheme 2024 (Draft)”, which will use funds of no more than HK$20 billion to purchase H shares as a source for awarding bonus shares. The specific award conditions of the incentive program will be linked to the company's 2024 operating revenue target. The meeting also passed a motion to the General Meeting to authorize the Board of Directors to deal with matters related to the H Share Award Trust Scheme, as well as a motion to amend the Company's registered capital and amend the Articles of Association. All approved motions will be submitted to the General Meeting for consideration. The Meeting finally decided to hold the 2023 General Meeting and the Second Class A and H Class Shareholders' Meeting in 2024.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more